ARGX - Regeneron's high-dose Eylea argenx's Vyvgart injectable among latest approvals in Japan
2024-01-18 07:00:29 ET
More on Argenx SE, Bayer, etc.
- Regeneron Pharmaceuticals Inc. (REGN) 42nd Annual JPMorgan Healthcare Conference - (Transcript)
- Why I Expect Regeneron To Keep Delivering For Investors In 2024 (Upgrade)
- argenx: Back To Earth After 2 Clinical Trial Failures
- Bayer to cut 'many' management jobs in deal with worker groups
- RBC ups Regeneron to outperform; cites Eylea patent win, Dupi sales
For further details see:
Regeneron’s high-dose Eylea, argenx’s Vyvgart injectable among latest approvals in Japan